Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT Combined With Radioactive Stent in Unresectable Extrahepatic Cholangiocarcinoma
NCT07916870Recruiting
- Start
- May 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of hemoporfin in extrahepatic cholangiocarcinoma (eCCA). Primary endpoint: Tumor response and biliary patency evaluated by RECIST v1.1 up to 24 months. Started May 2025; status: recruiting.
02
Drugs
hemoporfin
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on NCT07916870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07916870.